Hybrid cells formed by fusion of Epstein - Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate allogeneic T-cell responses in vitro

Tissue Antigens

Volumn 68, Issue 2, 2006, Pages 115-126

  Cywinski, A L ^a   Dunnion, D J ^a   Teobald, I ^a   Tucker, V C ^a   Browning, M J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Allogeneic; Co stimulation; Fusion; Hybrid; Immunotherapy; Tumour; Vaccine

Indexed keywords

ABATACEPT; B7 ANTIGEN; CD28 ANTIGEN; CD86 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOBLAST; BONE MARROW; CELL FUSION; CELL LINE; CELL LINEAGE; CELL PROLIFERATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HYBRID CELL; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; VIRUS LATENCY; B LYMPHOCYTE; BONE MARROW CANCER; CYTOLOGY; FEMALE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MELANOMA; METABOLISM; PHYSIOLOGY; T LYMPHOCYTE; TUMOR CELL LINE; UTERINE CERVIX TUMOR; VIROLOGY;

HUMAN HERPESVIRUS 4;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; BONE MARROW NEOPLASMS; CELL FUSION; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; HYBRID CELLS; LYMPHOCYTE ACTIVATION; MELANOMA; T-LYMPHOCYTES; UTERINE CERVICAL NEOPLASMS;

EID: 33747178107     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2006.00623.x     Document Type: Article

References (27)

1. Toes RE, Blom RJ, van der Voort E, Offringa R, Melief CJ, Kast WM. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996: 56: 3782-7.
2. Hrouda D, Todryk SM, Perry MJ et al. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer. BJU Int 2000: 86: 742-8.
3. Nanni P, Nicoletti G, De Giovanni C et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001: 194: 1195-205.
4. Curti A, Parenza M, Colombo MP. Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood 2003: 101: 568-75.
5. Thomas MC, Greten TF, Pardoll DM, Jaffee EM. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of any allogeneic vaccine. Hum Gene Ther 1998: 9: 835-43.
6. Pandha HS, Cook D, Greenhalgh R, Dalgleish A. Immumotherapy of murine prostate cancer using whole tumour cells killed ex vivo by cytosine deaminase/5-fluorocytosine suicide-gene therapy. BJU Int 2005: 95: 1336-43.
7. Suzuki T, Fukuhara T, Tanaka M et al. Vaccination of dendritic cells loaded with interleukin-12-secreating cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 2005: 11: 58-66.
8. Schendel DJ, Frankenberger B, Jantzer P et al. Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 2000: 7: 2007-14.
9. Shawler DL, Bartholomew RM, Garrett MA et al. Antigenic and immunologic characterization of an allogeneic colon carcinoma vaccine. Clin Exp Immunol 2002: 129: 99-106.
10. Raez LE, Cassileth PA, Schlesselman JJ et al. Induction of CD8 T-cell-interferon-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Ther 2003: 10: 850-8.
11. Raez LE, Cassileth PA, Schlesselman JJ et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004: 22: 2800-7.
12. Edwards PA, Smith CM, Neville AM, O'Hare MJ. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur J Immunol 1982: 12: 641-8.
13. Kozbor D, Lagarde AE, Roder JC. Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. Proc Natl Acad Sci USA 1982: 79: 6651-5.
14. Dunnion DJ, Cywinski AL, Tucker VC et al. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro. Immunology 1999: 98: 541-50.
15. Contreras-Brodin BA, Anvret M, Imreh S, Altiok E, Klein G, Masucci MG. B cell phenotype-dependent expression of the Epstein-Barr virus nuclear antigens EBNA-2 to EBNA-6: studies with somatic cell hybrids. J Gen Virol 1991: 72: 3025-33.
16. Kerr BM, Lear AL, Rowe M et al. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 1992: 187: 189-201.
17. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004: 4: 757-68.
18. Wang F, Gregory C, Sample C et al. Epstein-Barr virus-latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 co-operatively induce CD23. J Virol 1990: 64: 2309-18.
19. Uchida J, Yasui T, Takaoka-Shichijo Y et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1990: 286: 300-3.
20. Ding L, Shevach EM. Activation of CD4+T cells by delivery of the B7 constimulatory signal on bystander antigen-presenting cells (trans- costimulation). Eur J Immunol 1994: 24: 859-66.
21. Marelli-Berg FM, Hargreaves RE, Carmichael P, Dorking A, Lombardi G, Lechler RI. Major histocampatibility complex class II-expressing endothelial cells induce allospecific non-responsiveness in naïve T cells. J Exp Med 1996: 183: 1603-12.
22. Marelli-Berg FM, Frasca L, Imami N, Lombardi G, Lechler RI. Lack of T cell proliferation without induction of non-responsiveness after antigen presentation by endothelial cells. Transplantation 1999: 68: 280-7.
23. Smythe JA, Fink PD, Logan GJ, Lees J, Rowe PB, Alexander IE. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity. J Immunol 1999: 163: 3239-49.
24. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 1977: 270: 347-9.
25. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemic cell line with positive Philadelphia chromosome. Blood 1975: 45: 321-34.
26. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA, McCarthy RE. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukaemia. Cancer 1965: 18: 522-9.
27. Gey GO, Coffman WD, Kubicek MT. Tissue culture studies of the proliferative capacity of cervical carcinoma and normal epithelium. Cancer Res 1952: 12: 264.